Glaukos Corporation

GKOSleader

Glaukos invented the MIGS (micro-invasive glaucoma surgery) category with iStent, and is expanding into sustained-release drug delivery (iDose TR) and keratoconus treatment (Photrexa).

⇄ Compare

产品与营收

产品营收占比

营收构成 ($370M)

静态数据（加载实时财务…）

MIGS & Corneal Health (US) (72%)

International (28%)

业务板块构成与主要客户

产品详情

iStent (MIGS)52%

World's smallest FDA-approved medical device — tiny titanium stent implanted in eye during cataract surgery to lower IOP in glaucoma.

iDose TR (Sustained-release)25%

Travoprost intracameral implant providing 18-month drug delivery for glaucoma — no daily eye drops needed.

Photrexa (Corneal Cross-linking)23%

FDA-approved drug for keratoconus cross-linking — combined with UV light to halt corneal thinning.

供应链关系

竞争对手

alcon

MIGS device market

影响: major

合作伙伴

Abbott Laboratories

Cataract procedure integration

影响: significant

宏观与市场背景

헬스케어行业新闻

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化剂

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

点击「获取 AI 分析」以获得 Glaukos Corporation 的 AI 供应链分析。

企业信息

总部

San Clemente, California, USA

成立时间

1998

员工人数

1,400

官网

glaukos.com

行业概况 — 헬스케어

行业新闻